New Data on Oral DR Therapy

Daniel Su, MD

Show Description +

Daniel Su, MD, discusses post-hoc data on APX3330 (Ocuphire Pharma), an orally administered therapy under investigation to treat diabetic retinopathy.

Posted: 5/20/2024

Keywords:

retina-meeting-recap

•

APX3330

•

Ocuphire Pharmaceuticals

•

oral therapy

•

Diabetic Retinopathy

Up Next

Name: New Data on Oral DR Therapy
Uploaded: 2024-05-20T20:56:36+00:00
Description: Daniel Su, MD, discusses post-hoc data on APX3330 (Ocuphire Pharma), an orally administered therapy under investigation to treat diabetic retinopathy.

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Imaging AMD: Microperimetry and OCT

Giulia Corradetti, MD

SriniVas R. Sadda, MD, Steps in as ARVO President

Vas Sadda, MD

Gene Therapy for Wet AMD: Pharmacodynamic Changes

Ramanath Bhandari, MD

Faricimab in the Real World: 2 Years of Data

Aamir Aziz, MD

Addressing the AMD Epidemic

Emily Chew, MD

Managing Concurrent Wet AMD and GA

Ted Leng, MD

A Look at Three-Year Data for Pegcetacoplan

Ashkan Abbey, MD

The Latest Data on Photobiomodulation

Todd Schneiderman, MD

A Subretinal Implant for GA: Improving Vision

Mahi Muqit, MD

Optogenetics for RP: 12-Month Data

Allen Ho, MD

Back to All Videos

New Data on Oral DR Therapy

Daniel Su, MD

Daniel Su, MD, discusses post-hoc data on APX3330 (Ocuphire Pharma), an orally administered therapy under investigation to treat diabetic retinopathy.

Posted: 5/20/2024

Keywords:

retina-meeting-recap

•

APX3330

•

Ocuphire Pharmaceuticals

•

oral therapy

•

Diabetic Retinopathy

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

New Data on Oral DR Therapy

Up Next

New Data on Oral DR Therapy

More From ARVO: 2024 Coverage